GHCM
SRPT icon

Glen Harbor Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Glen Harbor Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$33K Buy
442
+136
+44% +$16.1K ﹤0.01% 1264
2019
Q2 		$47K Hold
306
– – ﹤0.01% 1254
2019
Q1 		$36K Buy
306
+34
+13% +$4.37K ﹤0.01% 1243
2018
Q4 		$30K Buy
+272
New +$34K ﹤0.01% 1209

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Glen Harbor Capital Management's SRPT Position: Q3 2019 in Review

Glen Harbor Capital Management increased its Sarepta Therapeutics (SRPT) stake by 44% in Q3 2019, buying an estimated $16.1K and bringing the position to 442 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #1264.

Glen Harbor Capital Management first reported a position in SRPT in Q4 2018 and has held it in 4 quarters since. The position peaked at $47K in Q2 2019. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Glen Harbor Capital Management held 442 shares of Sarepta Therapeutics worth $33K as of Q3 2019.
  • Glen Harbor Capital Management bought 136 Sarepta Therapeutics shares in Q3 2019, an estimated $16.1K.
  • Sarepta Therapeutics made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1264 holding.
  • Glen Harbor Capital Management first reported a position in Sarepta Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Glen Harbor Capital Management's Sarepta Therapeutics position peaked at $47K in Q2 2019.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.